Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (a foreign private issuer) on September 5, 2017. The filing incorporates by reference a press release dated September 5, 2017, regarding regulatory developments for the company's product candidate, ApoGraft.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The primary material event disclosed is the U.S. Food and Drug Administration (FDA) granting Orphan Drug Status to Cellect's ApoGraft for the treatment of Acute Graft-versus-Host Disease (GvHD) and Chronic GvHD.
Guidance, Outlook, and Risks
The filing incorporates the "Forward Looking Statements" section of the attached press release by reference. No specific financial guidance, management commentary on operations, or detailed risk factors are provided within the text of this Form 6-K itself.
Investor Verification Checklist
- Verify the specific indications approved under the Orphan Drug Status designation for ApoGraft.
- Review the full text of the attached press release (Exhibit 99.1) for details on the FDA decision and future development plans.
- Confirm the status of the company's Registration Statements on Form S-8 and Form F-3 referenced in the filing.
- Check subsequent filings for any financial impact or clinical trial updates related to this regulatory milestone.